Guideline/Drug Updates and Errata
The RxPrep Course Book is published annually. Information in the Course Book is up to date at the time of publishing, but drug information can change rapidly. Refer to the Updates on this page for NAPLEX-relevant information that becomes available before the next RxPrep Course Book is published. Guideline updates that may be relevant to NAPLEX are included. If we find anything that needs a correction or clarification in the RxPrep Course Book it will be included in the Errata table on this page.
Guideline/Drug Updates: 2020 RxPrep Course Book
NAPLEX-relevant updates from June 2019-May 2020
|Chapter 20: Immunizations|
|p. 322-328||Guideline Update November 2019|
Prevnar 13 is no longer routinely recommended in those ≥ 65 years of age. It can be administered based on shared clinical decision making between the patient and healthcare provider. A single dose of Prevnar 13 is still recommended for immunocompromised patients ≥ 6 years old if not previously received (see Study Tip Gal p. 328).
The update above applies to the following content:
|Chapter 23: Infectious Diseases II: Bacterial Infections|
|p. 382||Guideline Update October 2019|
The American Thoracic Society and Infectious Diseases Society of America have published updated guidelines for the Diagnosis and Treatment of Adults with Community-acquired Pneumonia. Key changes that can impact testing include:
Outpatient CAP Treatment
Inpatient CAP Treatment
|p. 384||Guideline Update February 2020|
The Centers for Disease Control and Prevention and the National Tuberculosis Controllers Association have published updated guidelines for the Treatment of Latent Tuberculosis Infection.
Regimens with shorter durations (e.g., 3 or 4 months) are preferred due to higher completion rates and less risk of hepatotoxicity when compared to longer courses of isoniazid (INH).
|Chapter 26: Human Immunodeficiency Virus|
|p. 418||Guideline Update December 2019|
Dolutegravir/lamivudine (Dovato) was added to the “Recommended Initial Regimens” as the first approved two-drug regimen. Dovato is only recommended for the following patients:
|p. 419||Guideline Update December 2019|
The recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV have been updated. Dolutegravir can now be used with 2 NRTIs as a preferred treatment in pregnancy. The true incidence of neural tube defects in the United States from dolutegravir is unknown but is lower than previously reported.
In the section on Regimens for Antiretroviral-Naïve Pregnant Women:
|p. 433||Labeling Change|
Emtricitabine/tenofovir alafenamide (Descovy) has been FDA-approved for the indication of pre-exposure prophylaxis (PrEP).
|Chapter 42: Chronic Obstructive Pulmonary Disease|
|p. 617||Guideline Update January 2020|
The 2020 Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) was published. There were no significant changes impacting the 2020 RxPrep Course Book content.
|Chapter 44: Diabetes|
|p. 639-642||Guideline Update January 2020|
The 2020 American Diabetes Standards of Care update was published. Key changes that can impact testing include:
Treatment for Type 2 Diabetes
|p. 649||New Drug Approval||Semaglutide (Rybelsus) has been approved as the first oral GLP-1 agonist.|
|p. 659||Labeling Change||The room temperature stability of Toujeo pen has changed to 56 days.|
|p. 660||New Drug Approval|
The FDA approved two novel formulations of glucagon for the treatment of hypoglycemia:
Corrections or clarifications for the 2020 RxPrep Course Book
|Chapter 1: Preparing for NAPLEX with RxPrep|
|p. 10 and p. 26|
In the Dose Conversions section of the Required Formulas Checklist (p. 10), the Required Formulas Sheet (p. 26) and the Required Formulas tear-out (at the back of the RxPrep Course Book), the page number for Calcium Salts and Aminophylline ↔ Theophylline should be p. 183.
|Chapter 15: Compounding I|
The section on "Media-Fill Test" should include this statement: "Media-fill testing must be performed initially during training and at least annually for low- and medium-risk level compounding and semiannually for high-risk compounding."
|Chapter 16: Compounding II|
The title "Hydrophobic Solvents" (p. 263) is incorrectly placed. Alcohols (p. 263) and Glycols (p. 264) are hydrophilic solvents. Oils and Fats (p. 264) are hydrophobic solvents.
|Chapter 17: Compounding III|
The section on "Melting Point Order" should say: "For any formulation, if melting ingredients, melt the ingredient with the highest melting point prior to adding the ingredient/s with lower melting points." The bullet underneath should say: "Line up the ingredients by the melting point temperature, and melt in that order, starting with the highest melting point."
|Chapter 27: Dyslipidemia|
In the Key Drugs Guy for Select Drugs/Conditions that can Raise LDL and/or Triglycerides, "atypical antipsychotics" should be listed under "increased LDL and TG."
|Chapter 35: Anemia|
For the Key Drugs Guy titled “Select Drugs that Can Cause Hemolytic Anemia,” all drugs in the front and back box are “must know” for testing. Valproic acid should be removed and replaced with sulfonamides.
|Chapter 43: Tobacco Cessation|
The 12-week schedule for nicotine gum and lozenge is missing from the table:
|Chapter 44: Diabetes|
The Study Tip Gal titled "Initiating Basal-Bolus Insulin" is intended to serve as an example and should have the following instructions: "Start a basal-bolus regimen with Lantus and Humalog in a 70 kg patient using a starting dose of 0.6 units/kg/day."
|Chapter 49: Osteoporosis, Menopause & Testosterone Use|
The Bisphosphonates section in the Drug Summary for Osteoporosis Treatment and Prevention Study Tip Gal should include this statement:
|Chapter 62: Oncology II|
In the second paragraph of the section titled "Hormonal Therapies for Prostate Cancer," the second sentence should say "ADT is achieved with either a gonadotropin-releasing hormone (GnRH) antagonist (alone) or a GnRH agonist (initially taken with an antiandrogen)."